Histone Deacetylase 6 can impede oncolytic viral replication in glioma.

Supplemental Figures

Hiroshi Nakashima[1,8], Johanna K. Kaufmann[1,8,9], Pin-Yi Wang[2], Tran Nguyen[1], Maria-Carmela Speranza, Kazue Kasai[1], Kazuo Okemoto[3], Akihiro Otsuki[4], Ichiro Nakano[3], Soledad Fernandez[5], William F. Goins[6], Paola Grandi[6], Joseph C. Glorioso[6], Sean Lawler[1], Timothy P. Cripe[2], and E. Antonio Chiocca[1,7]

[1] Department of Neurosurgery; Brigham and Women's Hospital; Boston, MA, 02115, USA

[2]Division of Hematology/Oncology/BMT; Nationwide Children's Hospital; Columbus, OH, 43205, USA

[3] Department of Neurosurgery; The Ohio State University Medical Center; Columbus, OH, 43210, USA

[4] Division of Anesthesiology and Critical Care Medicine; Tottori University

Faculty of Medicine; Yonago, Tottori, 683-8504, Japan

[5] Department of Biomedical Informatics; The Ohio State University; Columbus, OH, 43210, USA

[6] Department of Neurosurgery; University of Pittsburgh Cancer Institute/UPCI; Pittsburgh, PA, 15232, USA

[7] Corresponding author: eachiocca@partners.org

[8] Co-first author

[9] current address: Genocea Biosciences, Inc.; Cambridge, MA, 02140, USA



Figure 1S. Dose-response cytotoxicity of rQNestin34.5 with tubacin and CI994 drugs

A. data are same as those in **Figure 1D**. LDH cytotoxicity assay at the 3d post-infection of rQNestin34.5 in U251 in the presence of tubacin (0, 1, 2 and 5μM; starting at 14h before infection). Error bars represent means ± SD. **B.** LDH cytotoxicity assay at the 5d post-infection of rQNestin34.5 in U251 in the presence of CI994 (0, 1 and 3μM; starting at 14h before infection). Asterisks in plots represent significant differences (***p<0.001, **p<0.01, *p<0.05) by one-way ANOVA with Turkey's multiple comparisons tests.



Figure 2S. Time-lapse fluorescence confocal microscopy observation of HSV1 VP26-GFP.

Time-lapse z-stack images capture started after infection of RFP-lamp1 expressing U251 cells by a VP26-GFP expressing HSV-1 at 1h in ice-cold temperature, followed by washing unattached viruses. Cells were pretreated with tubacin (15h; in **D-F, J-L**) and/or IFNβ (14h; in **G-L**). tubacin was added in cultured media during the time-lapse analyses. Time (hh:mm) at left upper in each image indicate the time after infection. **Figure 5 A-D** correspond to **B, E, H and L** in **Figure 2S**. scale bar indicates 20 µm.

A



B



C



D



E



F



G



H



I



J



K



L





Figure 3S. Acetylation of αTubulin in orthotopic brain tumors after TA.

Tubulin acetylation in a mouse brain tumor after administration of control solution vs. two mice brain tumors after administration of TA is shown. Tubastatin A (TA) (50 mg per kg body weight) was administered i.p. every day for five days starting 4 days after GBM30 (100,000 cells per mouse) injection in Nu/nu mice brains. TA administration was continued then every other day until harvest of brain tumors at the 15 day time point. Tissues were homogenized in RIPA buffer (50mM Tric-HCl pH8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and protease inhibitor cocktail) before Western Blot analysis using antibodies against αTubulin and acetylated αTubulin (see detailed WB analyses in materials and methods section).